Valuation: GSK plc

Market Cap 73.41B 507B 96.98B 86.14B 80.56B 138B 9,338B 140B 975B 377B 4,756B 364B 356B 15,274B P/E 2026 *
14.2x
P/E 2027 * 11.7x
Enterprise Value 94.65B 653B 125B 111B 104B 178B 12,040B 181B 1,257B 486B 6,132B 469B 459B 19,694B EV / Sales 2026 *
2.79x
EV / Sales 2027 * 2.59x
Free-Float
92.75%
Yield 2026 *
3.8%
Yield 2027 * 4.09%
1 day-2.72%
1 week-2.62%
1 month-4.66%
3 months-7.22%
6 months-12.29%
Current year-7.56%
1 week 50.15
Extreme 50.15
51.55
1 month 48.9
Extreme 48.9
52.41
Current year 48.7
Extreme 48.7
63.24
1 year 46
Extreme 46
63.24
3 years 33.33
Extreme 33.33
63.24
5 years 30.69
Extreme 30.69
63.24
10 years 30.69
Extreme 30.69
63.24
Manager TitleAgeSince
Chief Executive Officer 52 2025-12-31
Director of Finance/CFO 64 2023-04-30
Compliance Officer - 2018-07-31
Director TitleAgeSince
Director/Board Member 52 2026-05-05
Director/Board Member 64 2017-12-31
Chairman 67 2019-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.72%-2.62% - - 97.46B
-0.58%-2.80%+39.18%+113.42% 1,031B
-2.09%-4.20%+39.37%+67.13% 638B
-0.38%-1.89%+6.44%+75.45% 462B
-0.66%-2.55%+59.99%+40.61% 359B
-0.03%-3.96%+23.63%+40.70% 335B
-1.58%-0.76%+13.50%+26.44% 273B
-2.02%-2.97%-3.25%+9.88% 253B
-2.28%+1.31%+37.80%+54.46% 228B
-0.61%-1.16%+33.12%+99.68% 185B
Average -1.30%-0.36%+27.75%+58.64% 418.21B
Weighted average by Cap. -1.10%-0.35%+30.69%+69.99%

Financials

2026 *2027 *
Net sales 33.92B 234B 44.81B 39.8B 37.22B 63.86B 4,315B 64.74B 450B 174B 2,197B 168B 165B 7,058B 35.5B 245B 46.9B 41.65B 38.95B 66.83B 4,515B 67.75B 471B 182B 2,300B 176B 172B 7,386B
Net income 5.19B 35.82B 6.86B 6.09B 5.7B 9.77B 660B 9.91B 68.92B 26.68B 336B 25.75B 25.19B 1,080B 6.21B 42.84B 8.2B 7.29B 6.81B 11.69B 790B 11.85B 82.43B 31.91B 402B 30.8B 30.13B 1,292B
Net Debt 21.24B 147B 28.06B 24.93B 23.31B 39.99B 2,702B 40.54B 282B 109B 1,376B 105B 103B 4,420B 18.52B 128B 24.46B 21.73B 20.32B 34.86B 2,355B 35.34B 246B 95.16B 1,200B 91.85B 89.86B 3,853B
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
Date Price Change Volume
26-09-30 R$50.15 -2.72% 18
26-09-29 R$51.55 +0.90% 1
26-09-25 R$51.09 -0.70% 25
26-09-24 R$51.45 -0.10% 10
26-09-23 R$51.50 -.--% 2
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
18.32GBP
Average target price
21.75GBP
Spread / Average Target
+18.71%

Quarterly revenue - Rate of surprise